Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04628780 · ClinicalTrials.gov registry record · Phase 1
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT04628780 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 37 participants.
The verdict
NCT04628780, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic, and potential clinical benefit of PF-07209960, an anti-PD-1 targeting IL-15 fusion protein, in participants with selected locally advanced or metastatic solid tumors for whom no standard therapy is available, or would not be an appropriate option in the opinion of the participant and their treating physician, or participants who have refused standard therapy. The study contains 2 parts, single agent Dose Escalation (Part 1) to determine the recommended dose of PF-07209960, followed by Dose Expansion (Part 2) in selected tumor types at the recommended dose.
Interventions
- BIOLOGICAL PF-07209960
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2020-12-16 |
| Est. Completion | 2023-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04628780
The ClinicalTrials.gov registry entry for NCT04628780 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-07209960 is the first listed.
NCT04628780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04628780 about?
NCT04628780 is a clinical study titled "Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors". This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic, and potential clinical benefit of PF-07209960, an anti-PD-1 targeting IL-15 fusion protein, in participants with sele...
What is the current status of trial NCT04628780?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2020-12-16. Estimated completion is 2023-05-26.
What interventions are being tested in trial NCT04628780?
The interventions under investigation include: PF-07209960 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04628780?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.